Publication | Closed Access
1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease
24
Citations
0
References
2019
Year
InflammationGastrointestinal PharmacologyImmunologyGastroenterology– EfficacyPhase 2MedicineInflammatory DiseaseDigestive System Diseases
No additional data available for this publication yet. Check back later!